Navigation Links
World's Top Gene Synthesis Companies Establish Tough Biosecurity Screening Protocol

World's Top Gene Synthesis Companies Form International Gene Synthesis Consortium (IGSC) to Coordinate Best Practices in Risk Reduction Five Member Companies Represent 80 Percent of Worldwide Gene Synthesis Capacity

(PRWEB) November 19, 2009 -- Five of the world’s leading gene synthesis companies today announced agreement that they will apply a common screening protocol to promote biosecurity in the gene synthesis industry. By screening the sequences of synthetic gene orders and the customers who place them, the companies aim to support government efforts to prevent the misuse of gene synthesis technology. Blue Heron Biotechnology, DNA2.0, GENEART, GenScript and Integrated DNA Technologies together represent approximately 80 percent of the global gene synthesis capacity. They have formed the International Gene Synthesis Consortium (IGSC) to coordinate ongoing best practices development and to work together with governments and others concerned to promote the beneficial application of gene synthesis technology and to safeguard biosecurity.

“We are proud to announce the formation of the International Gene Synthesis Consortium and equally proud of the commitment to the secure and safe synthesis of DNA it demonstrates,” said John Mulligan, Founder and CSO of Blue Heron Biotechnology. “The depth and breadth of expertise in gene synthesis represented by the participating companies, in concert with our dedication to policy based on sound science and thoughtful leadership, will enable us to shape the growth of a safe gene synthesis industry poised to help address the technological needs of the 21st century.”

“Safety and security are a chief priority for all of the IGSC companies, as the growth of the gene synthesis industry depends on an impeccable safety record. Each of the five founding companies has demonstrated a strong commitment to the safe delivery of synthetic DNA by implementing strong internal biosecurity practices,” said Dr. Ralf Wagner, CEO and CSO of GENEART. “We hope that the IGSC will help to encourage effective collaboration with government and policy organizations and promote internationally consistent approaches to safety and security in gene synthesis.”

“Each of the IGSC companies have worked over the past several years to implement internal sequence and customer screening processes, while contributing to the larger conversation amongst government agencies, policy organizations and the broader scientific community about developing an internationally coordinated approach to biosecurity,” said Nick Yan, Vice President, Marketing of GenScript USA. “Recognizing that achieving real gains in biosecurity requires harmonization of screening and other practices, we have drafted a harmonized screening protocol and decided to form the IGSC in an effort to coordinate ongoing work toward shared best practices in the gene synthesis industry."

The IGSC’s “Harmonized Screening Protocol for Gene Sequence & Customer Screening to Promote Biosecurity” establishes the five core components that each IGSC company will apply to promote the safe use of synthetic genes:

  • Gene Sequence Screening: The complete DNA sequence of every synthetic gene order is to be screened against a Regulated Pathogen Database developed by the consortium and one or more of the internationally coordinated sequence reference databanks (i.e., NCBI/GenBank, EBI/EMBL or DDBJ). Amino acid sequences of possible translation products for each synthetic gene ordered will also be screened.
  • Gene Customer Screening: A complete and thorough screening of each potential gene synthesis customer will be conducted to establish identity and clearance for delivery of genes ordered, in accordance with national guidelines. The screening protocol assigns special considerations to the ordering of Select Agent genes.
  • Record Keeping: The IGSC companies will keep all screening, customer and order records for at least eight years.
  • Order Refusal & Reporting: IGSC companies reserve the right to refuse to fill any order and to notify authorities upon identifying potentially problematic orders, coordinating efforts with local and national law enforcement and intelligence agencies.
  • Regulatory Compliance: IGSC companies comply with all applicable laws and regulations governing the synthesis, possession, transport, export and import of gene synthesis and other products.

“Gene synthesis is the technology driver that will enable research institutions, companies and even individuals or small teams of scientists to develop solutions to the great challenges of our age, such as climate change, world hunger and pandemic disease. Gene synthesis itself provides us with powerful new opportunities to combat the threat of bioterrorism,” said Jeremy Minshull, president of DNA2.0. “We won’t tolerate attempts to misuse gene synthesis technology to threaten the safety of any community. We scrutinize our orders to ensure that our customers are using our products for their potential benefits.”

“The founding companies of the IGSC have been working hand-in-hand with government and with the greater community of scientists and policy advocates to share our expertise in gene synthesis and to help us all devise the most effective biosecurity practices,” said Damon Terrill, Senior Vice President & General Counsel for International Legal and Regulatory Affairs for Integrated DNA Technologies. “For over three years, that collaboration has included close consultation with the Federal Bureau of Investigation and the Departments of Homeland Security and State, as well as with governments in Europe, especially. We encourage all companies who conduct gene synthesis to adopt the IGSC’s approach to sequence and customer screening, and we invite any company with significant business in gene synthesis to join us in the effort.”

About the IGSC
The International Gene Synthesis Consortium (IGSC) represents the gene synthesis industry. For more information please visit .


Read the full story at

Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Related biology technology :

1. Diabetics: 3tailer Partners with MyGlucoHealth on World's 1st Blood Glucose Meter with Wireless Bluetooth for Diabetes
2. Winter Park Home to World's Foremost Producers of Large-Scale Decontamination Equipment
3. GreenHouse Debuts the World's First E-Fuel MicroFuelerTM in Los Angeles
4. A-WIT Technologies Releases World's First Low Cost C Stamp(TM) Based Biotechnology Laboratory in a Box
5. The World's Leading IP Strategists Revealed
6. World's First Website for Patients to Share Diagnostic-Quality Medical Images
7. Lumidigm Biometric Sensor Included in Popular Science Best of What's New for 2008 : Venus Series Fingerprint Sensor Called a Breakthrough Product by the World's Largest Science and Technology Magazine
8. Convey Computer™ Corporation Launches World's First Hybrid-Core Computer at SC08 Conference
9. TRIDELITY Display Solutions Partners With Two Of The World's Leading Imaging Software Companies
10. Can Algae Biofuels Satisfy the World's Growing Biofuel Needs? Upcoming Webinar Shares the Latest Commercialization Strategies and Challenges
11. Polymathic Analytical Labs Debuts at World's Largest Medical Design & Manufacturing Exhibition
Post Your Comments:
Related Image:
World's Top Gene Synthesis Companies Establish Tough Biosecurity Screening Protocol
(Date:12/1/2015)...  Symic, a clinical-stage biotherapeutics company developing multiple compounds ... announced that it has secured $25 million in a ... its lead candidates SB-030 and SB-061. The financing was ... all existing major investors, as well as several new ... by Symic to over $43 million since being founded ...
(Date:12/1/2015)... Texas (PRWEB) , ... December 01, 2015 , ... Matthew ... his new post, VerMilyea will oversee all IVF lab procedures as well ... and fertility preservation. , “We traveled 7,305 miles to Auckland, New Zealand to bring ...
(Date:11/30/2015)... ... November 30, 2015 , ... Global Stem Cells Group ... in the Santiago Marriott. The Global Stem Cells Group GMP facility is equipped ... of qualified medical researchers and practitioners, experienced in administering stem cell protocols using ...
(Date:11/30/2015)... -- Partnership includes an MPP ... the u niversity , s Solid Drug ... cale - up through ... Africa , where licensees based anywhere in the world will have the right ... Africa , where licensees based anywhere in the world will have ...
Breaking Biology Technology:
(Date:11/2/2015)...  SRI International has been awarded a contract of ... to the National Cancer Institute (NCI) PREVENT Cancer Program ... modern testing and support facilities, and analytical instrumentation to ... studies to evaluate potential cancer prevention drugs. ... Drug Development Program is an NCI-supported pipeline to bring ...
(Date:10/29/2015)... 2015  Connected health pioneer, Joseph C. Kvedar ... technology-enabled health and wellness, and the business opportunities that ... The Internet of Healthy Things . Long before ... existed, Dr. Kvedar, vice president, Connected Health, Partners HealthCare, ... moving care from the hospital or doctor,s office into ...
(Date:10/27/2015)... 27, 2015 Synaptics Inc. (NASDAQ: SYNA ), ... Google has adopted the Synaptics ® ClearPad ® ... power its newest flagship smartphones, the Nexus 5X by ... --> --> Synaptics works ... strategic collaboration in the joint development of next generation ...
Breaking Biology News(10 mins):